Heparin-induced thrombocytopenia (HIT) is a serious, thrombotic condition occurring in approximately 1%-5% of patients exposed to heparin (1) . Approximately 20%-50% of patients with HIT who are treated by heparin cessation will develop new thrombosis, and mortality in HIT is approximately 20%-30% (2) . Heparin should be discontinued immediately in HIT, and alternative anticoagulation should be initiated (3) . The direct thrombin inhibitors argatroban (4, 5) and lepirudin (6) have been shown in multicenter, prospective studies to improve clinical outcomes in HIT. Warfarin is not recommended as an acute treatment in HIT because it can lead to venous limb gangrene and skin necrosis (7) (8) (9) . However, patients who are adequately anticoagulated with a direct thrombin inhibitor may be transferred to warfarin for continued anticoagulation when HIT is no longer acute and platelets have recovered substantially (3) .
Routinely, warfarin dosage is individualized according to a patient's response to the drug, as assessed by the international normalized ratio (INR) (10) , and direct thrombin inhibitors are monitored using the activated partial thromboplastin time (aPTT) (4) (5) (6) . Because direct thrombin inhibitors also affect the INR, their combined use with warfarin or other vitamin K antagonists may prolong the INR beyond that produced by the oral anticoagulant alone (11) (12) (13) (14) (15) . The extent of the INR prolongation depends on the residual vitamin K-dependent protein activity, the plas- 279 Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia Marcie J. Hursting, PhD,* Bruce E. Lewis ma concentration of the direct thrombin inhibitor, and the sensitivity of the assay reagent (11) (12) (13) (14) (15) (16) . From studies conducted in healthy subjects, guidelines have been developed for monitoring the transition from argatroban to warfarin (12, 17) or other oral anticoagulants (15) using the INR. However, the effect of argatroban on peritransitional INRs in patients with HIT has not been well described. Also how well physicians, in the absence of guidelines, transfer patients with HIT from argatroban to warfarin therapy has not been reported. We report the peritransitional INRs, aPTTs, anticoagulant dosing patterns, and clinical outcomes of 165 patients with HIT who were transitioned from argatroban to warfarin therapy, in the absence of guidelines, during a prospective study (4) of argatroban anticoagulation in HIT.
METHODS AND MATERIALS

Patients and Anticoagulant Therapy
Patients with HIT who transitioned from argatroban to warfarin therapy were identified from the multicenter study Argatroban-911 (4) wherein 304 patients with clinically diagnosed HIT (or a history of serologically confirmed HIT and requiring anticoagulation) were treated prospectively with argatroban. The prospective study was approved by the Institutional Review Board at each participating center, and patients provided written informed consent. We reviewed study case records to identify all patients who received warfarin. The starting times/dates of argatroban and, when available, warfarin dosing were compared to select patients who started warfarin while receiving argatroban. The selected patients who completed the prospective study were included in our study population.
Following discontinuation of heparin, patients received continuous intravenous argatroban (GlaxoSmithKline, Philadelphia, PA) at a starting dose of 2 mcg/kg/min. Argatroban is hepatically metabolized (18) , and a lower starting dose was allowed in patients with hepatic impairment. The dose was adjusted (up to 10 mcg/kg/min, maximum) to achieve an aPTT 1.5-3 times the baseline value (not to exceed 100 seconds). The aPTT was measured daily and 2 hours after any dose change. Argatroban was continued for up to 14 days, until the underlying condition was resolved, or anticoagulation was provided by warfarin. The physician investi-gators made all decisions regarding warfarin usage. INRs were measured when clinically indicated during warfarin administration and until argatroban had been discontinued for 24 hours.
Assessments
For this analysis, peritransitional outcomes included new thrombosis, amputation, death, or major bleeding that occurred during argatroban and warfarin cotherapy or on the calendar day following argatroban cessation. New thrombosis was identified on the basis of clinical signs and symptoms and documented when technically possible by using noninvasive techniques such as ventilation/perfusion scans or ultrasound examinations. Major bleeding was defined as overt bleeding in association with a hemoglobin decrease of 2.0 g/dL or greater that led to a transfusion of 2 or more units, or that was intracranial, retroperitoneal, or into a prosthetic joint. Major bleeding was also assessed during argatroban infusion and for 30 days after its discontinuation.
The quality of the transition to warfarin was prospectively defined as "uneventful" if a therapeutic INR on warfarin monotherapy (i.e., at the completion of the transition) was achieved within 5 days after initiating warfarin, in the absence of new thrombosis, major bleeding, or administration of vitamin K or fresh-frozen plasma with the intent to reverse anticoagulation during argatroban and warfarin cotherapy. Patients who achieved a therapeutic INR after 5 days in the absence of complications were considered to have undergone an uneventful transition of longer duration. The first INR measured 4-24 hours after the discontinuation of argatroban, which has an elimination half-life of 39-51 minutes in healthy subjects (18) , was taken as the post-transitional INR on warfarin monotherapy. An INR of 1.9-3.5 on warfarin monotherapy was prospectively defined as "therapeutic."
Data Sets and Analyses
All patients were included in analyses of baseline characteristics, peritransitional outcomes, anticoagulant dosing patterns, INRs, and aPTTs. Patients with an INR assessed 4-24 hours after argatroban cessation were evaluable for analysis of the quality of the transition.
Descriptive statistics for peritransitional anticoagulant dosing patterns, aPTTs, and INRs were computed overall, for patients stratified by the presence or absence of peritransitional outcomes, and for evaluable patients stratified by their posttransitional INR (i.e., <1.9, 1.9-3.5, >3.5). For anticoagulant doses, INRs and aPTTs, the "baseline" value was obtained before initiation of argatroban, the "argatroban monotherapy" value was the last value obtained during argatroban therapy and before initiation of warfarin, and the "argatroban/warfarin cotherapy" value was the last value obtained before argatroban was discontinued. An INR reported as ">X" in case records was assigned a value of "X" for analyses. All available data were used in computations; sample sizes may have been reduced owing to missing data. Unless otherwise noted, data are reported as the median with associated 5-95th percentile values (the median only may be mentioned in the text if the 5-95th percentile values appear in a table).
RESULTS
Patients
From 304 patients treated with argatroban during a prospective study in HIT (4), we identified 165 patients who were transitioned from argatroban to warfarin therapy and completed the study. These patients comprised the study population.
An additional 15 patients received warfarin during the prospective study yet had incomplete dosing records that precluded determination of the temporal relationship between warfarin and argatroban administration. Also, an additional five patients initiated warfarin while receiving argatroban yet did not complete the study because argatroban was discontinued when consent was withdrawn, life support was withdrawn, intravenous lines could not be maintained (n=1, each), or for a planned procedure or surgery (n=2). None of these additional patients had a clinical outcome during argatroban infusion or within 4 days of its cessation. Hence our selection criteria did not systematically exclude patients who had poor outcomes temporally associated with argatroban treatment.
The study population included 93 (56%) females, and the median (5-95th percentile) patient age was 64 (33-77) years. Baseline median aPTT and INR values were 29.9 (21.8-75.3) seconds (n=159) and 1.3 (0.9-3.1) (n=40), respectively. Patients at baseline typically had moderate thrombocytopenia (median platelet count, 78 × 10 9 /L), which was recovering before warfarin was initiated (median platelet count, 132 × 10 9 /L) ( Table 1 ). The most frequent indications for warfarin therapy were deep venous thrombosis or pulmonary embolism (n=63), arterial or venous thrombosis (n=27), thromboprophylaxis or anticoagulation (n=19), and HIT or hypercoagulability (n=16).
Peritransitional Anticoagulation
Argatroban monotherapy at a median dose of 2.0 mcg/kg/min prolonged the median aPTT and INR to 59.8 seconds and 3.2, respectively, and was continued for a median of 3 days before warfarin was initiated ( Table 1) . Immediately before warfarin was initiated, 20 (15.7%) of 127 patients with available data had an INR greater than 5.
Patients received warfarin as a median initial dose of 5 mg followed by 3.8 mg/day thereafter. Argatroban and warfarin therapy overlapped for a median of 4 days. During the overlap period, 86 (54%) of 159 patients with available data had an INR greater than 5 (median maximum INR, 5.3; maximum value, 189). The highest reported INRs were calculated from data obtained using reagents with international sensitivity indices (ISIs) of approximately 2 or more. The median maximum aPTT was 68.6 seconds, and no patient had an aPTT greater than 130 seconds. Immediately before cotherapy ended, the median argatroban dose was 1.5 mcg/kg/min (associated median aPTT, 59.9 seconds), and the median INR was 4.0.
Within a median 10-12 hours after argatroban cessation, the median aPTT (36.0 seconds) was closely approaching the pretreatment value, and the median warfarin monotherapy INR (2.3) was in the therapeutic range.
Peritransitional Outcomes
No patient experienced major bleeding peritransitionally or within 30 days of argatroban cessation. (While not considered a peritransitional outcome, pretransitional major bleeding following a surgical procedure occurred in one patient who was successfully treated with 2 units of red blood cells.) Peritransitionally, 1 (0.6%) patient died following asystole, 2 (1.2%) underwent amputation secondary to ischemic complications of HIT, and 16 (9.7%) had new thrombosis (one of whom also underwent amputation). The new thrombosis occurred most often (seven events) on the day after argatroban discontinuation.
Patients with, versus without, a peritransitional adverse outcome had lower median platelet counts at baseline (39 vs. 83 × 10 9 /L) and before warfarin initiation (106 vs. 137 × 10 9 /L), had a greater median duration of overlap (6 vs. 3 days), and had greater median INRs during cotherapy (4.5 vs. 3.9) ( Table 1 ). The patient groups were otherwise generally similar regarding aPTTs and other aspects of their transition.
Quality of the Transition
Post-transitional INRs were lacking in 57 patients, five of whom had peritransitional new thrombosis and two received vitamin K. We analyzed the quality of the transition in the remaining 108 patients stratified by their post-transitional INR (i.e., <1.9, 1.9-3.5, or >3.5).
Among the evaluable patients, 43 (40%) had a therapeutic INR at the completion of the transition ( Table 2 ). Figure 1 presents their peritransitional INR and aPTT response patterns. Comp-arable numbers of the remaining patients had subtherapeutic (n=34) or supratherapeutic (n=31) INRs post-transitionally. There was no obvious across-group trend in new thrombosis. Vitamin K or fresh frozen plasma was used most often (9.7%) in the supratherapeutic INR group; however, no major bleeding occurred in any group. Overall, in the absence of guidelines, 34 (31%) of 108 patients uneventfully transitioned from argatroban to warfarin therapy within 5 days (n=32) or longer (n=2; 7 and 9 days, respectively).
The supratherapeutic INR group, relative to the other groups, had a lower median platelet count at the initiation of warfarin (90 vs. 166-173 × 10 9 /L), required a lower median argatroban dose during monotherapy (1.0 vs. 2.0 mcg/kg/min) and cotherapy with warfarin (0.75 vs. 1.6-1.8 mcg/kg/min) to achieve comparable aPTTs, and received less warfarin daily (median 
DISCUSSION
This analysis represents the first comprehensive characterization of peritransitional outcomes, anticoagulant dosing patterns, INRs, and aPTTs in HIT patients transitioned from argatroban to warfarin therapy. Argatroban, a direct thrombin inhibitor, is indicated in the United States as an anticoagulant for the prophylaxis or treatment of thrombosis in patients with HIT (4,5) and in patients with or at risk for HIT undergoing percutaneous coronary intervention (19) . HIT patients treated with argatroban may require long-term anticoagulation with warfarin. Although argatroban and warfarin lack pharmacokinetic interactions (20) , these agents exert a combined effect on the INR (11, 12, 14) , the laboratory measure routinely used to monitor warfarin therapy. We evaluated the peritransitional INRs (and aPTTs) in 165 HIT patients who transitioned from argatroban to warfarin therapy and estimated how well their transitions, conducted in the absence of guidelines, occurred. The patients were identified from a prospective study of argatroban therapy in HIT (4) . Because that study was not de-signed to evaluate the effect of argatroban on the INR, many patients lacked a post-transitional INR. However, we evaluated peritransitional outcomes in all 165 patients and the quality of the transition in 108 evaluable patients.
We found that INRs greater than 5 were common, and INRs even greater than 20 occurred, during argatroban monotherapy or argatroban/warfarin cotherapy with concurrent therapeutic aPTTs. Although clinical laboratories reported all INRs less than 5 as exact values, some of the higher INRs were reported as "greater than a value," and hence the highest INRs are underrepresented. Thromboplastin reagents with relatively high (≥ 2) ISIs, which are not generally recommended (21) , were associated with the highest INRs. Despite these INRs, only one (0.6%) patient experienced major bleeding during argatroban monotherapy, and no patient experienced major bleeding during or after the transition. Hence traditional paradigms concerning bleeding risk and INRs during warfarin therapy (10) are not commutable to HIT patients receiving argatroban monotherapy or argatroban/warfarin cotherapy. Furthermore, the aPTT, which is sensitive to argatroban yet relatively insensitive to warfarin therapy (12) , can be used effectively for monitoring argatroban before and during the transition period in HIT patients.
In the absence of specific guidelines, physicians transferred patients from argatroban to warfarin therapy with an acceptably low complication rate in HIT, and clinical decision-making did not systematically result in over-or underdosing warfarin. Specifically, similar numbers of patients had subtherapeutic or supratherapeutic INRs post-transitionally, and approximately one third of the patients achieved therapeutic INRs without complication within one week of initiating the transition. The platelet count is a significant independent predictor of adverse outcomes in HIT (22) . Indeed, the 18 (10.9%) patients in our analysis who died or suffered amputation or new thrombosis peritransitionally had more severe thrombocytopenia than the patients without complications. During argatroban/warfarin cotherapy, the level of anticoagulation between these patients groups was similar in terms of the aPTT, and INRs were slightly greater in patients with events, which is inconsistent with anticoagulant under-dosing leading to their events. However, seven (of 16, 44%) new thrombotic events occurred on the day after argatroban was stopped, suggesting the possible premature discontinuation of the parenteral anticoagulation in some patients.
Patients with hepatic impairment, compared with healthy subjects, have an approximately fourfold decreased argatroban clearance and require lower doses to achieve the same level of anticoagulation (18) . The evaluable patients with post-transitional supratherapeutic INRs, relative to the other patients, required reduced argatroban doses to attain similar aPTTs, suggesting a greater presence of hepatic impairment. These patients also received a reduced daily warfarin dose, perhaps related to concerns of hepatic dysfunction potentiating the response to warfarin (10) , and were generally sicker as evidenced by lower platelet counts. Because hepatic impairment increases the elimination half-life of argatroban (18) , some post-transitional supratherapeutic INRs may have reflected the continued combined effect of argatroban and warfarin, rather than warfarin alone. Indeed among patients whose post-transitional supratherapeutic INR was re- (3), the initiation of warfarin in patients with acute HIT should be delayed until the platelet count is at least 100 × 10 9 /L and only begun if the patient is clinically improving and adequately anticoagulated with an alternative parenteral agent. Also warfarin should be initiated using a maintenance dose and overlapped with the parenteral agent for at least 5 days. Treatment with the alternative anticoagulant should be continued until a target INR has been achieved for at least 2 consecutive days, and until the platelet count has reached a stable plateau. Most, but not all, patients in our analysis received a daily warfarin dose of less than 5 mg, had a platelet count greater than 100 × 10 9 /L when warfarin was initiated (which was typically at least 3 days after initiating argatroban), and overlapped warfarin and argatroban therapy for at least 4 days.
According to guidelines for estimating the INR on warfarin monotherapy from the INR on argatroban/warfarin cotherapy, a cotherapy INR of greater than 4 in subjects receiving argatroban 2 mcg/kg/min or less generally reflects a therapeutic INR on warfarin alone (12, 17) . In our analysis, most (85%) HIT patients with a posttransitional subtherapeutic INR lacked an INR greater than 4.0 immediately before argatroban was discontinued. The guidelines also suggest that when the target cotherapy INR is achieved after the appropriate duration of overlap, argatroban should be discontinued, and the INR should be checked 4-6 hours later to ensure an actual therapeutic INR value reflective of warfarin monotherapy. We would add that in patients with hepatic impairment, it may be prudent to wait longer before checking the INR and to consider concurrently checking the aPTT to confirm that the effects of argatroban are negligible.
It is anticipated that the implementation of current recommendations and guidelines (3, 12, 17) will further facilitate smooth transitions from argatroban to a therapeutic INR on warfarin in HIT patients. This remains to be established, perhaps using results from this analysis as a comparative benchmark.
